The company has started distribution of the generic version of GlaxoSmithKline’s Requip XL.
Actavis CEO Doug Boothe said, "The launch of Ropinirole Extended-Release Tablets showcases Actavis’ commitment in bringing new products to market to benefit both patients and payors. We are proud to play a part in lowering healthcare costs through the introduction of quality generic products."
According to IMS Health, Requip XL, 2mg, 4mg, 6mg, 8mg and 12mg, had US sales of approximately $59.4m for the 12 months ending 31 December 2011.